Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. [PDF]
Hepatocellular carcinoma (HCC) is among the most common cancer types and causes of cancer related mortality worldwide. Almost 50% of all HCC cases globally are attributable to chronic hepatitis B virus (HBV) infection. The incidence rates of HCC in untreated Asian subjects with HBV infection was estimated to be 0.2% in inactive carriers, 0.6% for those
Baran B.
europepmc +4 more sources
Proportion of patients who used nucleos(t)ide analogues (A) and the survival of patients according to the use of nucleos(t)ide analogues (B).
Joong-Won Park (816550) +11 more
core +1 more source
A meta-analysis of controlled clinical trials comparing peginterferon-α plus nucleos(t)ide analogs versus peginterferon-α monotherapy for HBsAg clearance or seroconversion in patients with chronic hepatitis B. [PDF]
BackgroundChronic hepatitis B virus (HBV) infection remains a major global health challenge. Peginterferon-α (PEG-IFN-α) and nucleos(t)ide analogs (NAs) are standard therapies used to suppress HBV replication.
Zhu S, Yang Z, Wang Y, Cai X, Qin C.
europepmc +2 more sources
Nucleos(t)ide analogs to treat patients with positive hepatitis B virus deoxyribonucleic acid and normal alanine transaminase: protocol for an open-label single-center randomized parallel controlled trial. [PDF]
Background Direct high-quality evidence remains absent on the benefits of HBeAg-negative chronic hepatitis B patients (CHB) with normal alanine transaminase (ALT) and positive HBV DNA after nucleos(t)ide analogs (NAs) treatment.
Zhou J +5 more
europepmc +2 more sources
Outcome of nucleos(t)ide analog intervention in patients with preventive or on‐demand therapy for hepatitis B virus reactivation [PDF]
AbstractPreventive or on‐demand nucleos(t)ide analog (NA) therapy can prevent severe hepatitis related to hepatitis B virus reactivation (HBV‐R). However, it is unclear if NA can be safely stopped in such patients after cytotoxic therapies or during immunosuppressive therapies.
Akihiro Tamori +9 more
openaire +2 more sources
Although rare patients with chronic hepatitis B can achieve HBsAg loss on oral nucleos(t)ide analog (NA), the optimal timing of stopping oral NAs safely has been considered when HBsAg and HBV DNA are negative in the serum because HBsAg loss induced by ...
Hye Jeong Cho +4 more
doaj +1 more source
Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis
Chronic hepatitis B infection induces progressive liver disease. Before nucleos(t)ide analogs (NUCs) became established as a safe and effective treatment for hepatitis B, it was difficult to suppress the activity of the hepatitis B virus (HBV). Currently, many patients with hepatitis or cirrhosis associated with HBV are treated with NUCs for an ...
Koichi, Honda +2 more
openaire +2 more sources
Clinical Characteristics and Factors Associated with Hair Loss Severity in Chronic Hepatitis B Patients Receiving Pegylated Interferon-Alpha: A Retrospective Cohort Study. [PDF]
Xiaodan Wang, Zhenzhen Yan, Cuie Liu, Yanqing GaoDepartment of Dermatology and Venereology, Beijing You An Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Xiaodan Wang, Email bzmcwangxd@ccmu.edu.cnObjective: To ...
Wang X, Yan Z, Liu C, Gao Y.
europepmc +2 more sources
BACKGROUND AND AIMS: In patients with chronic hepatitis B virus (HBV) infection, persistent exposure to high concentrations of antigen can disrupt T-cell functions.
Viganò, Mauro +26 more
core +2 more sources
We evaluated whether nucleos(t)ide analog (NA) influences the risk of non-hepatocellular carcinoma (non-HCC) malignancies in patients with chronic hepatitis B (CHB). A total of 9867 patients with CHB were followed up for ≥12 months for the occurrence of any type of malignancy between 1998 and 2013. Patients who received NA for ≥180 days were defined as
Kim, Soon Sun +11 more
openaire +2 more sources

